Director / PCA Shareholding

RNS Number : 9911P

Futura Medical PLC

15 October 2019

 

Director / PCA Shareholding

15 October 2019

Futura Medical Plc (AIM: FUM) ("Futura" or "the Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today received notification that on 14 October 2019, Charlotte Barder, a person closely associated (PCA) with James Barder, the Company's CEO, sold 66,500 ordinary shares of 0.2 pence in the Company ("Ordinary Shares") at a price of 28.5 pence per share and repurchased 66,500 Ordinary Shares at a price of 28.55 pence per share.  These trades were carried out as part of a "Bed and ISA" process, allowing Charlotte to move her existing shareholding into an ISA.

Following these trades James Barder's beneficial holding remains unchanged at 968,472 ordinary shares with an aggregate beneficial and non-beneficial holding of 1,085,972 Ordinary Shares, representing 0.53 per cent. of the current total voting rights of the Company.  James Barder also has options over 1,750,000 Ordinary Shares.

Further details are contained within the notification below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]

Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel: [phone]

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension.  FM57 is progressing on track, with headline data expected by the end of 2019.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Charlotte Barder
2	Reason for the notification
a)	Position/status	PCA of James Barder, CEO
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical Plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.2 pence
	Identification code	ISIN: GB0033278473
b)	Nature of the transaction	Transfer of 66,500 Ordinary Shares, via sale and repurchase
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			28.55p	66,500 (sale)
			28.5p	66,500 (purchase)
d)	Aggregated information
	- Aggregated volume - Price - Total - Aggregated volume - Price - Total	66,500 (sale) 28.55p £18,985.75 66,500 (purchase) 28.5p £18,952.50
e)	Date of the transaction	14 October 2019
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

DSHQELFFKBFXFBZ